Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

London, UK

Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.

Latest From Andrew McConaghie

As Vyvgart Surges To Blockbuster Status, Argenx Maps Out Expansion Plans

The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.

Immune Disorders Commercial

Idorsia Asset Sell Off Continues But Future Still Up In The Air

A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.

FDA Delay Will Not Push Rocket Pharma Off Its Trajectory

The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.

Companies Clinical Trials

Best-In-Class In MASH? Boehringer’s Hopes Raised By Glucagon/GLP-1 Phase II Results

The results could help BI and Zealand Pharma challenge in the MASH field, though analysts are wary of claims around fibrosis improvement.

Commercial Companies

Moderna Prepares To Enter The RSV Vaccine Fray

Its mRNA-based RSV vaccine challenger has a more convenient administration than GSK and Pfizer’s frontrunners, but may not compete on durability of protection.

Commercial Launches

Arcus And Gilead Make GI Cancers The Focus Of Their TIGIT Hopes

Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.

Companies Cancer
See All
UsernamePublicRestriction

Register